Literature DB >> 21301489

Do fibrates truly preserve kidney function?

Suneel M Udani, George L Bakris.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21301489     DOI： 10.1038/nrendo.2011.14

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 2.  Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Authors:  Giovanni F M Strippoli; Sankar D Navaneethan; David W Johnson; Vlado Perkovic; Fabio Pellegrini; Antonio Nicolucci; Jonathan C Craig
Journal:  BMJ       Date:  2008-02-25

3.  Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

Authors:  Ravi Retnakaran; Carole A Cull; Kerensa I Thorne; Amanda I Adler; Rury R Holman
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

4.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Authors:  T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech
Journal:  Diabetologia       Date:  2010-11-04       Impact factor: 10.122

5.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment.

Authors:  M J Landray; J Thambyrajah; F J McGlynn; H J Jones; C Baigent; M J Kendall; J N Townend; D C Wheeler
Journal:  Am J Kidney Dis       Date:  2001-09       Impact factor: 8.860

7.  Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  P L Drury; R Ting; D Zannino; C Ehnholm; J Flack; M Whiting; R Fassett; J-C Ansquer; P Dixon; T M E Davis; C Pardy; P Colman; A Keech
Journal:  Diabetologia       Date:  2010-07-30       Impact factor: 10.122

8.  Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.

Authors:  Carmichael Angeles; Bernard P Lane; Frederick Miller; Edward P Nord
Journal:  Am J Kidney Dis       Date:  2004-09       Impact factor: 8.860

9.  Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.

Authors:  Jean-Claude Ansquer; R Neil Dalton; Elisabeth Caussé; Dominique Crimet; Karine Le Malicot; Christelle Foucher
Journal:  Am J Kidney Dis       Date:  2008-04-02       Impact factor: 8.860
  9 in total
  2 in total

1.  Lipid-lowering agents in chronic kidney disease: do fibrates have a role?

Authors:  Yuli Huang; Yunzhao Hu
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

Review 2.  Lipid mediators in diabetic nephropathy.

Authors:  Swayam Prakash Srivastava; Sen Shi; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2014-09-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.